Barlesi F, et al. CheckMate 817: First-line nivolumab + ipilimumab in patients with ECOG PS 2 and other special populations with advanced NSCLC. Abstract OA04.02. WCLC 2019, 7-10 september, Barcelona, Spanje.
Datopotamab deruxtecan bij gevorderde HR+/HER2- en tripelnegatieve borstkanker
jun 2024 | Borstkanker